Literature DB >> 33296649

The Master Regulator Protein BAZ2B Can Reprogram Human Hematopoietic Lineage-Committed Progenitors into a Multipotent State.

Karthik Arumugam1, William Shin2, Valentina Schiavone1, Lukas Vlahos2, Xiaochuan Tu3, Davide Carnevali1, Jordan Kesner2, Evan O Paull2, Neus Romo1, Prem Subramaniam2, Jeremy Worley2, Xiangtian Tan2, Andrea Califano4, Maria Pia Cosma5.   

Abstract

Bi-species, fusion-mediated, somatic cell reprogramming allows precise, organism-specific tracking of unknown lineage drivers. The fusion of Tcf7l1-/- murine embryonic stem cells with EBV-transformed human B cell lymphocytes, leads to the generation of bi-species heterokaryons. Human mRNA transcript profiling at multiple time points permits the tracking of the reprogramming of B cell nuclei to a multipotent state. Interrogation of a human B cell regulatory network with gene expression signatures identifies 8 candidate master regulator proteins. Of these 8 candidates, ectopic expression of BAZ2B, from the bromodomain family, efficiently reprograms hematopoietic committed progenitors into a multipotent state and significantly enhances their long-term clonogenicity, stemness, and engraftment in immunocompromised mice. Unbiased systems biology approaches let us identify the early driving events of human B cell reprogramming.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BAZ2B; cell fusion; chromatin remodeling; gene regulatory network; hematopoietic stem cells; master regulators; reprogramming; single cell sequencing; systems biology

Year:  2020        PMID: 33296649      PMCID: PMC8049840          DOI: 10.1016/j.celrep.2020.108474

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  98 in total

Review 1.  AP-1 subunits: quarrel and harmony among siblings.

Authors:  Jochen Hess; Peter Angel; Marina Schorpp-Kistner
Journal:  J Cell Sci       Date:  2004-12-01       Impact factor: 5.285

Review 2.  Cell-fusion-mediated reprogramming: pluripotency or transdifferentiation? Implications for regenerative medicine.

Authors:  Daniela Sanges; Frederic Lluis; Maria Pia Cosma
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

3.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

4.  Hhex is Required at Multiple Stages of Adult Hematopoietic Stem and Progenitor Cell Differentiation.

Authors:  Charnise Goodings; Elizabeth Smith; Elizabeth Mathias; Natalina Elliott; Susan M Cleveland; Rati M Tripathi; Justin H Layer; Xi Chen; Yan Guo; Yu Shyr; Rizwan Hamid; Yang Du; Utpal P Davé
Journal:  Stem Cells       Date:  2015-05-27       Impact factor: 6.277

5.  GPI-80 defines self-renewal ability in hematopoietic stem cells during human development.

Authors:  Sacha Leandra Prashad; Vincenzo Calvanese; Catherine Yao Yao; Joshua Kaiser; Yanling Wang; Rajkumar Sasidharan; Gay Crooks; Mattias Magnusson; Hanna Katri Annikki Mikkola
Journal:  Cell Stem Cell       Date:  2014-11-13       Impact factor: 24.633

6.  Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency.

Authors:  Wee-Wei Tee; Mercedes Pardo; Thorold W Theunissen; Lu Yu; Jyoti S Choudhary; Petra Hajkova; M Azim Surani
Journal:  Genes Dev       Date:  2010-12-15       Impact factor: 11.361

7.  Molecular basis of histone tail recognition by human TIP5 PHD finger and bromodomain of the chromatin remodeling complex NoRC.

Authors:  Cynthia Tallant; Erica Valentini; Oleg Fedorov; Lois Overvoorde; Fleur M Ferguson; Panagis Filippakopoulos; Dmitri I Svergun; Stefan Knapp; Alessio Ciulli
Journal:  Structure       Date:  2014-12-18       Impact factor: 5.006

8.  MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs.

Authors:  C David Wood; Hildegonda Veenstra; Sarika Khasnis; Andrea Gunnell; Helen M Webb; Claire Shannon-Lowe; Simon Andrews; Cameron S Osborne; Michelle J West
Journal:  Elife       Date:  2016-08-04       Impact factor: 8.140

9.  A comparison of methods for differential expression analysis of RNA-seq data.

Authors:  Charlotte Soneson; Mauro Delorenzi
Journal:  BMC Bioinformatics       Date:  2013-03-09       Impact factor: 3.169

10.  Heterokaryon-based reprogramming of human B lymphocytes for pluripotency requires Oct4 but not Sox2.

Authors:  Carlos F Pereira; Rémi Terranova; Natalie K Ryan; Joana Santos; Kelly J Morris; Wei Cui; Matthias Merkenschlager; Amanda G Fisher
Journal:  PLoS Genet       Date:  2008-09-05       Impact factor: 5.917

View more
  4 in total

1.  Crystal structure of the BAZ2B TAM domain.

Authors:  Yingying Feng; Sizhuo Chen; Mengqi Zhou; Jin Zhang; Jinrong Min; Ke Liu
Journal:  Heliyon       Date:  2022-07-06

2.  Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer.

Authors:  Aleksandar Obradovic; Diana Graves; Michael Korrer; Yu Wang; Sohini Roy; Abdullah Naveed; Yaomin Xu; Adam Luginbuhl; Joseph Curry; Michael Gibson; Kamran Idrees; Paula Hurley; Peng Jiang; X Shirley Liu; Ravindra Uppaluri; Charles G Drake; Andrea Califano; Young J Kim
Journal:  Clin Cancer Res       Date:  2022-05-13       Impact factor: 13.801

3.  Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages.

Authors:  Aleksandar Obradovic; Nivedita Chowdhury; Scott M Haake; Casey Ager; Vinson Wang; Lukas Vlahos; Xinzheng V Guo; David H Aggen; W Kimryn Rathmell; Eric Jonasch; Joyce E Johnson; Marc Roth; Kathryn E Beckermann; Brian I Rini; James McKiernan; Andrea Califano; Charles G Drake
Journal:  Cell       Date:  2021-05-20       Impact factor: 66.850

Review 4.  The emerging role of ISWI chromatin remodeling complexes in cancer.

Authors:  Yanan Li; Han Gong; Pan Wang; Yu Zhu; Hongling Peng; Yajuan Cui; Heng Li; Jing Liu; Zi Wang
Journal:  J Exp Clin Cancer Res       Date:  2021-11-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.